This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Subscribe To Our Newsletter & Stay Updated
